One of the reasons pancreatic cancer is more deadly than breast, brain, ovarian cancers is that the tumors often grow very close to blood vessels that you cannot live without. The goal of the West Virginia researchers led by Brian Boone, MD, is to shrink tumors away from blood vessels that would otherwise be unremovable by surgery.
Boone’s team analyzed data from 24 studies and evaluated the outcomes of 313 cases of pancreatic cancers that were borderline treatable with surgery and first treated with the new chemotherapy regimen called FOLFIRINOX.
The findings showed that more than 67 percent of the tumors included in the analysis responded well enough to the FOLFIRINOX that they could be completely surgically removed. In addition, the survival data showed that the patients treated with FOLFIRINOX and surgery survived an average of 22.2 months overall. Without the combination chemotherapy patients with tumors that could not be treated by surgery survived about 12 month based on Boone’s clinical experience.
Source: EurekAlert press release
No comments:
Post a Comment